Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca and Eli Lilly secure FDA fast-track status for Alzheimer’s drug
AZD3293 is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. In theory, a BACE inhibitor would prevent the buildup of beta-amyloid and may help slow or stop AD.
AZD3293 is an oral beta-secretase 1 cleaving enzyme (BACE) inhibitor. In theory, a BACE inhibitor would prevent the buildup of beta-amyloid and may help slow or stop AD.
Medivation is focused on the development and commercialization of medically innovative therapies to treat severe diseases that have limited treatment options. The company’s portfolio includes Xtandi (enzalutamide) capsules
The JV, which was initially announced in December 2015, will focus on the discovery, development and commercialization of new therapeutics to treat blood disorders, blindness, and congenital heart
The capsules are intended to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are not sufficient. Troxyca ER extended-release
Scientists at the Rockefeller University and the La Jolla Institute for Allergy and Immunology found evidence that suggests adult brain cells critical to learning and memory might be
Aquatrove is a Chicago based biotechnology company with focus on human reproductive health and fertility products. Through the deal, the Brussels, Belgium headquartered company will acquire Aquatrove’s international
The company will invest the amount over ten years to expand the site for the continued manufacturing of generic injectable medicines. Fresenius Kabi plans to break the ground
RBP-6000 is an investigational buprenorphine sustained-release formulation, which uses the company’s Atrigel delivery system Indivior said if granted marketing authorization in the US, the drug will provide a
The financing was co-led by RiverVest Venture Partners, Novo Ventures, Roche Venture Fund and GlaxoSmithKline’s corporate venture capital arm S.R. One. Tioma will use the proceeds from the
The phase III program is evaluating a two-drug regimen of dolutegravir (Tivicay) and lamivudine (Epivir) on about 1,400 men and women across the world versus the three-drug regimen